Cannabis Research
Liquisolid Cannabis Tablets Could Transform Medical Dosing
Add MyCannabis.com to your preferred sources on Google
For years, cannabis medicine has lived in two worlds: oils and soft gelatin capsules. While effective, both formats come with challenges, such as dosing variability, leakage risk, high manufacturing costs, and limited scalability. Now, new pharmaceutical research suggests a powerful alternative: liquisolid tablets.
A study1 titled “Liquisolids as a Platform for the Formulation of Cannabis Tablets” from researchers at the University of Bonn demonstrates how mesoporous silica-based liquisolid systems can transform sticky cannabis extracts into stable, free-flowing powders suitable for tablet production. The implications are significant. This technology could provide a more cost-effective, scalable, and standardized pathway for oral cannabis medicine, particularly for patients managing chronic pain, multiple sclerosis, insomnia, and other conditions requiring consistent dosing.
Let’s explore what this exactly means and why it matters.
What Is Liquisolid Technology?
Liquisolid technology is a pharmaceutical formulation approach designed to convert liquid or semi-solid active ingredients into dry, compressible powders.
Cannabis extracts, especially those rich in THC or CBD, are naturally oily and sticky. This makes them difficult to incorporate into traditional tablets. Historically, manufacturers have relied on liquid tinctures or soft gelatin capsules to deliver cannabinoids orally. However, both formats require specialized equipment and can be expensive to produce at scale.
Liquisolid systems solve this by using highly porous carrier materials, in this case, mesoporous silica, to absorb the liquid extract. The liquid becomes trapped within microscopic pores, turning what was once sticky into a powder that flows freely and can be compressed into tablets.
In the Bonn study, researchers used Syloid XDP 3050 silica to absorb cannabis extract at a ratio of 0.75 mL per gram. This powder was then combined with additional excipients to create tablets containing 10 mg of THC each.
The result? A tablet that behaves like a conventional pharmaceutical product but contains a previously difficult-to-tablet botanical extract.
Why Cannabis Tablets Have Been So Difficult To Make
Tableting cannabis extracts is not straightforward. When a formulation contains a high amount of liquid, it can weaken the structural integrity of the tablet. Common problems include:
- Low tensile strength (tablets break easily)
- Capping (tops separating from tablets)
- Delamination (layers splitting apart)
The challenge lies in balancing two competing goals of maintaining a high “overall liquid load” while still achieving a mechanically strong tablet.
The Bonn researchers addressed this by carefully optimizing excipients and compression parameters. They used a 65/35 volumetric ratio of liquid-loaded silica to microcrystalline cellulose, which served as both binder and filler. They also fine-tuned the disintegrant and lubricant levels to ensure tablet performance without sacrificing strength.
The final tablets achieved a tensile strength of 1.58 N/mm², strong enough for practical handling and distribution, while maintaining a remarkably high overall liquid load of 38.4%. In pharmaceutical terms, that’s impressive.
Optimizing Disintegration and Manufacturing
A tablet must do more than hold together. It must also break apart appropriately in the body to release the active ingredient.
The researchers found that a 4% concentration of Kollidon CL-F provided optimal disintegration performance. Too little disintegrant, and the tablet would dissolve slowly. Too much, and structural integrity could be compromised.
Swipe to scroll →
| Metric | Result | Why It Matters |
|---|---|---|
| THC Dose Per Tablet | 10 mg | Supports standardized medical dosing and repeatable patient outcomes. |
| Overall Liquid Load | 38.4% (V/V) | High loading enables meaningful cannabinoid delivery without softgels. |
| Tablet Tensile Strength | 1.58 N/mm² | Indicates tablets can withstand handling, packaging, and transport. |
| Optimal Disintegrant | 4% Kollidon® CL-F | Improves break-up in GI fluids for consistent cannabinoid release. |
| Lubricant Concentration | 0.5% Magnesium Stearate | Supports efficient manufacturing without suppressing dissolution. |
| Accelerated Stability | 30 days at 40°C (0% RH) | Suggests resistance to degradation under stress-storage conditions. |
| Estimated Refrigerated Shelf Life | > 3 years (modeled) | Supports longer distribution windows and reduced waste (requires real-time confirmation). |
They also identified 0.5% magnesium stearate as the most effective lubricant concentration. Lubricants are essential during manufacturing to prevent sticking to punches and dies, but excess amounts can interfere with dissolution.
Using a StylOne compaction simulator to model rotary press production, the team determined that applying precompression at roughly half the main compression pressure allowed for faster production speeds while maintaining tensile strength and minimizing defects.
In other words, this was not just a laboratory curiosity; it was engineered with scalability in mind.
Stability: A Critical Advantage for Cannabis Medicine
Cannabis formulations are notoriously sensitive to heat, light, oxygen, and humidity. Degradation of THC into CBN, for example, can alter potency and therapeutic effect.
One of the most encouraging findings from this research was stability. The liquisolid tablets remained stable for 30 days at 40°C and 0% humidity, both accelerated conditions used to simulate long-term storage. Under refrigerated conditions, stability is predicted to exceed three years.
For cannabis medicine, this is major. Long shelf life improves:
- Patient safety
- Dose consistency
- Supply chain reliability
- Global distribution feasibility
It also reduces product waste and improves regulatory compliance.
Why Liquisolid Cannabis Tablets Could Improve Medical Dosing
Standardization is one of the most persistent challenges in medical cannabis. Many patients rely on oils that require manual measurement, which introduces dosing variability. Soft gelatin capsules offer better consistency but are expensive to produce and require specialized encapsulation equipment.
Liquisolid tablets could offer the best of both worlds: pharmaceutical-grade precision with more accessible manufacturing costs.
For patients managing chronic pain, multiple sclerosis spasticity, neuropathy, or insomnia, consistent oral dosing is critical. A 10 mg THC tablet produced through a controlled liquisolid system may provide more predictable onset and duration than variable oil-based preparations.
Moreover, tablets are discreet, portable, and familiar to both patients and healthcare providers. That familiarity matters when integrating cannabis into mainstream medical systems.
Economic and Regulatory Significance
Beyond patient care, this research has economic implications. Soft gelatin capsules demand complex infrastructure and specialized materials. Liquisolid tablets, by contrast, can be manufactured using conventional tableting equipment already widely available in pharmaceutical facilities.
This lowers barriers to entry for manufacturers and may reduce production costs over time. In emerging medical cannabis markets cost-effective scalability is essential.
Additionally, regulators often prefer solid dosage forms because they offer precise dosing, uniformity, and validated manufacturing standards. Tablets are easier to test for weight variation, dissolution behavior, friability, and tensile strength compared to oils.
By providing a scalable alternative to soft gels, liquisolid technology could help standardize cannabis medicine in a way that aligns with pharmaceutical regulatory frameworks.
The Future of Oral Cannabis Formulation
Liquisolid systems are not limited to THC alone. The same technology could potentially be adapted for:
- CBD-dominant formulations
- Balanced THC/CBD ratios
- Minor cannabinoids
- Full-spectrum extracts
Because mesoporous silica absorbs and stabilizes liquid extracts, this platform may support broader cannabinoid delivery innovation.
The key achievement of the Bonn study is not merely the creation of a 10 mg THC tablet. It demonstrates that high-liquid-load cannabis extracts can be transformed into stable, mechanically sound, scalable tablet formulations, shifting the formulation conversation for cannabinoid medicine. Instead of asking how to package cannabis oils, researchers and manufacturers can now ask how to optimize solid oral dosage forms for improved bioavailability, patient adherence, and global distribution.
Final Thoughts
Liquisolid technology represents a quiet but important advancement in pharmaceutical cannabis development. By transforming sticky extracts into free-flowing, compressible powders, researchers have opened the door to standardized, stable, and scalable cannabis tablets.
For patients seeking consistent oral dosing, for manufacturers aiming to reduce production costs, and for regulators looking for reliable dosage forms, this platform offers a compelling alternative to soft gelatin capsules.
As cannabis medicine continues to mature, innovations like liquisolid tableting may play a central role in bridging the gap between botanical extracts and pharmaceutical precision, making standardized oral cannabis therapies more accessible to the people who need them most.
References:
1. Appelhaus, J., Wagner, K. G., & Steffens, K. E. (2026). Liquisolids as a platform for the formulation of cannabis tablets. International Journal of Pharmaceutics: X, 11, Article 100508. https://doi.org/10.1016/j.ijpx.2026.100508
